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Abstract
Calcium channels have been shown to play an important role in the pathogenesis of diabetic
nephropathy. The purpose of this study is to investigate the effect of T-type calcium channel blockers
in uninephrectomized diabetic rats. Two weeks after uninephrectomy, streptozotocin (65 mg/kg)
was given to male Sprague-Dawley rats to induce diabetes mellitus. In the succeeding days, four
groups of animals were randomized to receive 30 mg/kg mibefradil (Mib, T-type calcium channel
blocker), 30 mg/kg amlodipine (Aml, L-type calcium channel blocker), 10 mg/kg cilazapril (Cil,
angiotensin converting enzyme inhibitor) or 25 mg/kg Mib + 8 mg/kg Cil (M+C), which were delivered
daily by gavage (n = 6-8 for each group). At the fourth week, 24-hour urine, blood and kidney
samples were collected for examinations. Renal morphometric analyses and assay for type IV
collagen and laminin were performed. Untreated diabetic rats (DM) exhibited overt hyperglycemia,
proteinuria and albuminuria when compared with uninephrectomized (UNx) control (17.67 ±4.9 vs
2.97 ±0.72 µg/24 hours, p < 0.05), while Cil and M+C treated rats had significantly reduced urinary
protein excretion (Cil: 5.53 ±1.45, M+C: 3.87 ±0.88 vs DM: 17.67 ±4.9 µg/24 hours; p < 0.05,
respectively). Mibefradil alone also ameliorated albuminuria in DM rats (7.69 ±1.87 vs 17.67 ±4.9
µg/24 hours, p < 0.05). Histopathological study revealed significantly less glomerular matrix, laminin,
type IV collagen and proximal tubule cells (PTC) hypertrophy in the Cil and M+C groups when
compared with the DM group (Collagen IV: DM 7.3 ±0.65 vs Mib 4.82 ±0.78, Cil 4.11 ±0.74, M+C 2.
64 ±0.66, UNx 3.71 ±0.99, p < 0.05). Albuminuria, glomerular matrix accumulation and collagen IV
deposition were not changed in the Aml treated group. There was, however, significantly lower
creatinine clearance and laminin volume in the Aml group. In conclusion, our study demonstrated
that T-type calcium channel blockage reduced albuminuria and renal extracellular matrix
accumulation in experimental diabetic rats, suggesting an important role for T-type calcium channel
in the progression of diabetic nephropathy. Additional benefit can be achieved by combination
with an angiotensin converting enzyme inhibitor. The mechanism of action, however, requires further
investigation.
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INTRODUCTION
Calcium channel blockers (CCB) are effective anti-
hypertensive agents commonly used in patients with
diabetic mellitus. Unlike angiotensin converting enzyme
inhibitor (ACEi), its renoprotective effect in diabetic
patients remains unsettled (1). It has recently been shown
that T-type calcium channel is involved in glomerular
hypertrophy, mitogenesis and macromolecular traf-
ficking (2), implicating a critical role in the progression
of chronic renal diseases. In this study, we examined the
renoprotective effects of T-type CCB, mibefradil (Ro-
405967), in streptozotocin-induced diabetic rats, and
compared them with those of L-type CCB amlodipine,
ACEi cilazapril as well as the combination of mibefradil
and cilazapril.
SUBJECTS AND METHODS
Experimental animals
Thirty male Sprague-Dawley rats weighing 180 to 220 g
underwent uninephrectomy after being anesthetized using
intraperitoneal chloral hydrate. Two weeks after the
operation, streptozotocin (STZ, Sigma) 65 mg/kg was
injected intraperitoneally to induce diabetes mellitus.
Diabetes was defined as heavy glycosuria (3+ to 4+) and
severe hyperglycemia (> 16.7 mmol/L), which usually
appeared 48 hours after STZ administration. Another six
uninephrectomized rats were injected with isovolumic
buffered citrate solution and served as uninephrectomized
non-diabetic control (UNx). The diabetic rats were
randomly allocated to receive the following treatments
in the succeeding 4 weeks: mibefradil (Mib, 30 mg/kg/
day; n = 6), amlodipine (Aml, 30 mg/kg/day; n = 6),
cilazapril (Cil, 10 mg/kg/day; n = 8), combined mibefradil
and cilazapril (M+C, Mib 25 mg/kg/day, Cil 8 mg/kg/
day; n =7) and vehicle (DM, n = 7). All drugs or vehicle
were delivered daily by gavage from the day after being
confirmed as diabetic. Animals were kept in a pathogen-
free environment with free access to water and standard
rat chow.
Blood pressure was measured weekly by tail-cuff
method. After the 4-week treatment period, the animals
were kept in metabolic cages for 24-hour urine collection.
Blood samples were collected through the right carotid
artery. The animals were then sacrificed and the left
kidneys were removed, weighed, and fixed overnight in
4% buffered formaldehyde.
Measurement of biochemical parameters
Blood glucose, urinary protein, serum and urine creatinine
were measured in the clinical laboratory by an automatic
biochemical analyzer (Hitachi 7170, Japan). Creatinine
clearance (Ccr) was calculated according to the formula:
Ccr = urine creatinine x 24 hours urine volume/serum
creatinine. Urinary albumin level was determined by
radioimmunoassay (China Atomic Science Institution).
Plasma angiotensin converting enzyme activity was
measured by ultraviolet spectrophotometry.
Histopathological analysis
Renal tissue was embedded in paraffin, sectioned into
4 µm thickness and screened by periodic acid-Schiff
(PAS) and periodic acid silver methenamine (PASM)
staining. Relative area of glomerular matrix and height
of renal proximal tubular epithelial cells were measured
by an image analysis system (LEIKA, Germany). The
cumulative area of glomeruli and intraglomerular matrix
in 20 consecutive non-overlapping cortical fields on
PASM stained sections were measured under the
magnification of 20 x objective. The relative area of
glomerular matrix was defined as the ratio of the sum of
intraglomerular matrix to that of glomeruli. Cross sections
of proximal tubules in 10 consecutive non-overlapping
cortical fields under magnification of 10 x objective were
selected to determine the outer and inner diameters of
the tubules, the discrepancy between which was taken as
the height of proximal tubular epithelial cell.
Matrix components were demonstrated by immuno-
histochemical staining. After routine dewax and
rehydration, the sections were treated by 0.1% buffered
trypsin at 37 oC for 20 minutes for antigen retrieval.
Endogenous hydrogen peroxidase was quenched by 3%
H2O2/methanol. After blocking in 10% goat serum, the
sections were incubated with rabbit anti-rat collagen IV
and laminin polyclonal antibodies (a gift from the
Department of Pathology, Shanghai Medical University)
at room temperature for 30 minutes. The sections were
then treated with goat-anti-rabbit IgG conjugated
with horseradish peroxidase and developed by
3,3’-diaminobenzidine (DAKO) solution. Under
magnification of 10 x objective, 20 consecutive non-
overlapping cortical fields were analyzed morpho-
metrically for intraglomerular collagen IV and laminin
by LEIKA image analysis system.
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Statistical analysis
Data were presented as mean ±standard error. Data from
the six groups were analyzed by analysis of variance
(ANOVA) and the level of significance was defined as
p < 0.05.
RESULTS
Blood pressure
Results of the mean arterial pressure (MAP) measured
by tail-cuff method were listed in table 1. Though no
difference in MAP was found in Mib, Aml, Cil and M+C,
all these four groups had a significant decrease in MAP
compared with DM or UNx (all p < 0.05).
Blood glucose level
All STZ-injected rats had substantially elevated blood
glucose (all p < 0.05). Interestingly, it was lower in the
Cil and M+C group compared with the DM group (both
p < 0.05).
Proteinuria and albuminuria
All diabetic rats except in the M+C group showed
significantly higher urinary protein and albumin
excretion rate compared with the UNx (all p < 0.05).
The proteinuria, however, was decreased in all treated
groups (all p < 0.05), and even less in M+C and Cil than
that of Mib and Aml (all p < 0.05). Moreover, compared
with DM, the decreases in urinary albumin excretion rate
in rats treated with Mib, Cil and their combination (M+C)
were significant (p < 0.05). The difference in albuminuria
between Mib and Cil was not significant (p > 0.05)
(Table 1).
Creatinine clearance
There was elevated Ccr in all diabetic rats compared with
the UNx control (all p < 0.05). When compared with the
DM, it was decreased in all treated groups (all p < 0.05).
Ccr was significantly lower in the Cil and M+C groups
than that in the Mib and Aml groups (all p < 0.05)
(Table 1).
Ratio of kidney weight to body weight
Ratio of kidney weight to body weight (KW/BW) in each
group were: Mib 9.2 ±1.2, Aml 9.1 ±0.7, Cil 7.9 ± 0.5,
M+C 7.8 ±0.5, DM 9.6 ±0.9, UNx 6.8 ±0.7 x 10-3.
Significant difference was only detected between the DM
and the UNx group (p < 0.05).
Histopathological analyses
The results of morphometric examination for relative
glomerular matrix and height of proximal tubular cells
(PTC) were shown in table 2. The relative glomerular
matrix area was significantly higher in all diabetic groups
than that in UNx control (all p < 0.05). Compared with
that in UNx, PTC height was also increased in DM, Aml
Table 1.  General conditions and biochemical parameters in each group.
Experimental group n MAP Serum ACE activity Blood glucose Proteinuria Albuminuria Creatinine clearance
 (mmHg) (nM/min/mL) (mmol/L) (mg/24 h) (µg/24 h) (mL/min)
Mibefradil 6 110.3 ±5.81 140.4 ±13.4 25.6 ±1.71 27.2 ±9.71,2,3 7.69 ±1.871,2,3 2.53 ±0.331,2,3
Amlodipine 6 109.8 ±3.51 160.3 ±12.0 23.6 ±2.41 30.6 ±4.81,2,3 15.11 ±4.031,3 2.20 ±0.171,2,3
Cilazapril 8 107.2 ±3.11 45.6 ±8.71 20.1 ±2.81,2 21.8 ±3.21,2 5.53 ±1.451,2 1.81 ±0.271,2
Mibefradil+Cilazapril 7 113.1 ±4.71 34.5 ±4.51 20.5 ±0.91,2 18.1 ±4.82 3.87 ±0.881,2 1.88 ±0.281,2
Uninephrectomized diabetes 7 139.6 ±5.2 180.9 ±21.6 22.4 ±1.81 50.7 ±11.51 17.67 ±4.901 3.44 ±0.441
Uninephrectomized control 6 130.4 ±6.6 220.6 ±32.4 6.8 ±0.7 14.8 ±4.8 2.97 ±0.72 1.25 ±0.17
1p < 0.05 compared with uninephrectomized control.
2p < 0.05 compared with uninephrectomized diabetes.
3p < 0.05 compared with mibefradil+cilazapril.
Table 2.  Relative glomerular matrix area, height of PTC, and glomerular type IV collagen and laminin deposition.
Experimental group n Glomerular matrix PTC height (µm) Type IV collagen Laminin
Mibefradil 6 0.301 ±0.0251,3 4.99 ±0.271 4.82 ±0.782,3 5.06 ±0.981,2
Amlodipine 6 0.307 ±0.0261,3 5.20 ±0.211 6.54 ±0.751,3 5.35 ±0.671,2
Cilazapril 8 0.223 ±0.0301,2,3 3.89 ±0.242 4.11 ±0.742,3 3.87 ±1.022
Mibefradil+Cilazapril 7 0.191 ±0.0181,2 3.55 ±0.202 2.64 ±0.062 3.12 ±0.062
Uninephrectomized diabetes 7 0.322 ±0.0351 6.07 ±0.381 7.30 ±0.651 7.99 ±0.881
Uninephrectomized control 6 0.179 ±0.021 4.11 ±0.18 3.71 ±0.99 3.70 ±0.49
1p < 0.05 compared with uninephrectomized control.
2p < 0.05 compared with uninephrectomized diabetes.
3p < 0.05 compared with mibefradil+cilazapril.
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and Mib (all p < 0.05), while there was no difference for
Cil and M+C (p > 0.05). The expression of glomerular
type IV collagen and laminin were listed in table 2.
Positively stained area for type IV collagen was more
extensive in DM and Aml groups than that in UNx.
Furthermore, glomerular type IV collagen deposition in
M+C was less when compared with that in Mib and Cil
(both p < 0.05) (Fig. 1). Similarly, the positively stained
area of glomerular laminin in DM, Aml and Mib was
larger than that in UNx (all p < 0.05). Compared with
that in DM, it was smaller in all treated groups
(all p < 0.05) (Fig. 2).
DISCUSSION
Intraglomerular hypertension and hyperfiltration is an
important mechanism for progression of diabetic
nephropathy. Extracellular matrix (ECM) accumulation
caused by proteinuria and a variety of growth factors
could lead to glomerulosclerosis. Beside intensive
glycemic control, interventions targeting systemic and
intraglomerular hypertension, proteinuria and extra-
cellular matrix accumulation are also being actively
investigated (3).
Calcium channels are classified into L-, T-, P- and N-
type according to their activation characteristics.
Conventional calcium channel blockers are all of the L-
type, which can further be divided into three groups:
dihydropyridine (e.g., nifedipine, amlodipine, felodipine,
nicardipine, etc.), phenylalkylamines (e.g., verapamil),
and benzothiazepines (e.g., diltiazem). Despite their
potent antihypertensive effect, the protective effects for
progressive renal deterioration are still controversial.
Several studies have demonstrated a more potent anti-
proteinuria effect by non-dihydropyridine compared to
dihydropyridine CCB. The beneficial effects on
glomerular sclerosis and proteinuria, however, are still
inferior to those of ACEi (1). A body of evidence from
in vivo and in vitro studies showed that T-type
calcium channel plays an important role in some
pathophysiological changes of cardiovascular diseases.
Blockage of the channel results in blood pressure
reduction and attenuation of pathological cellular growth.
T-type calcium channel also mediates vascular smooth
muscle cell contraction (4). Blockage of T-type calcium
channel by Ro 40-5967 (mibefradil) could inhibit the
proliferation and hypertrophy of smooth muscle cell
while L-type CCB e.g. verapamil, amlodipine and
felodipine are devoid of such effect (5). Moreover, in
DOCA salt-induced (6) and spontaneous (7) hypertensive
rats, mibefradil significantly ameliorates proteinuria and
glomerular changes, indicating the role of T-type calcium
channel in kidney diseases. These effects of mibefradil
are related mostly to its effects on the reduction of
intracellular calcium level via inhibition of calcium influx
(9). They may also be mediated via inhibition of renin
secretion (8), inhibitory actions on protein kinase K
activity (10) and platelet aggregation (9). Improvement
of endothelial function (11), deactivation of sympathetic
nerve (12), decrease of vascular permeability (13) may
also be involved.
In this study, we found that blockage of T-type calcium
channel by mibefradil attenuated proteinuria and
glomerular hyperfiltration, i.e. elevated Ccr, in early stage
STZ-diabetic rats. Histological study also showed
significantly less glomerular matrix deposition compared
with controls. These data suggested a role for T-type
calcium channel in early diabetic nephropathy and are
in accord with the study of Cao et al, in which low-dose
mibefradil ameliorates hypertrophic changes of
mesenteric artery in STZ-diabetic rats without lowering
of systemic blood pressure (14).
As mibefradil may also affect the L-type calcium channel,
the possible involvement of L-type calcium channel by
mibefradil should be considered. The modest effect of
amlodipine on proteinuria and glomerular matrix
deposition, however, speaks to the contrary.
Diabetic nephropathy is caused by hyperglycemia, and
the therapeutic effect of ACEi is partly medicated by its
insulin sensitizing mechanism (15). The current study,
as well as our previous investigations using the same
model (16), also demonstrated that ACEi reduced blood
glucose level. Intervention on neither T-type nor L-type
calcium channel had such effect, suggesting that
improvement of insulin metabolism is not involved in
the therapeutic mechanisms of CCB.
With comparable systemic blood pressure reduction,
combination therapy with T-type CCB mibefradil and
ACEi cilazapril were more effective than mibefradil
alone in reducing proteinuria and glomerular ECM and
type IV collagen deposition. As for glomerular matrix
volume and positive-stained type IV collagen area,
cilazapril was less effective than that of combination
therapy. These overall results indicate that the therapeutic
effect of mibefradil on diabetic nephropathy is not
dependent on the renin-angiotensin system (RAS)
inhibition. This hypothesis is also supported by the results
of our previous study, in which mibefradil could cause a
similar degree of proteinuria and glomerular ECM
reduction in spontaneous hypertensive rats with STZ-
induced diabetes, whilst there were no obvious changes
in plasma angiotensin II and renal angiotensin type 1
receptor (AT1) expression level (Chinese Journal of
Nephrology, in press).
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Figure 1.  Immunohistological detection for glomerular deposition of type IV collagen in differently treated diabetic rats after uninephrectomy
( x 400 magnification).
Mib = mibefradil; Aml = amlodipine; Cil = cilazapril; M+C = combined treatment with mibefradil and cilazapril; DM = uninephrectomized
diabetes; UNx = uninephrectomized control.
Figure 2.  Immunohistological detection for glomerular deposition of laminin in differently treated diabetic rats after uninephrectomy ( x 400
magnification).
Mib = mibefradil; Aml = amlodipine, Cil = cilazapril; M+C = combined treatment with mibefradil and cilazapril; DM = uninephrectomized
diabetes; UNx = uninephrectomized control.
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In summary, blockage of T-type calcium channel could
ameliorate proteinuria and glomerular extracellular
matrix accumulation in rats with early diabetic
nephropathy. The more potent effect of T-type over L-
type CCB suggests a more important role of the former
in the pathogenesis of early diabetic nephropathy. Further
study is necessary to examine the mechanism of action
of T-type CCB.
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